Jpmorgan Chase & CO Seelos Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.16 - $1.64 $944 - $9,676	5,900 Added 24.03%	30,457 $5,000
Q2 2023 Aug 11, 2023	BUY	$0.66 - $1.22 $2,970 - $5,490	4,500 Added 22.44%	24,557 $29,000
Q1 2023 May 11, 2023	BUY	$0.59 - $1.04 $11,800 - $20,800	20,000 Added 35087.72%	20,057 $13,000
Q2 2022 Aug 11, 2022	SELL	$0.51 - $0.93 $23,496 - $42,846	-46,072 Reduced 99.88%	57 $0
Q1 2022 May 11, 2022	SELL	$0.84 - $1.71 $43,108 - $87,757	-51,320 Reduced 52.66%	46,129 $39,000
Q4 2021 Feb 10, 2022	BUY	$1.59 - $2.38 $94,903 - $142,057	59,688 Added 158.07%	97,449 $158,000
Q3 2021 Nov 12, 2021	BUY	$1.69 - $2.89 $63,816 - $109,129	37,761 New	37,761 $91,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $40.5M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.